Companies
Scribe Therapeutics
engineered CasX (X-edit) CRISPR platform, partnered with Sanofi on in-vivo editing.
- Country
- United States
Coverage
| CN | EU | US | |
|---|---|---|---|
| genome-engineering | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $128.7 million IPO (July 2026) and ~$150 million raised prior to IPO | endpoints.news · medcitynews.com · sec.gov |
| Funding | Grant funding from CIRM of up to ~$25.7 million | medcitynews.com · biospace.com · scribetx.com · sec.gov |
| Headcount | 88-89 employees as of mid-2026 | stockanalysis.com |
| Headquarters | 1150 Marina Village Parkway, Alameda, CA 94501, United States | medcitynews.com · sec.gov |
| Regulatory approval | Australian TGA clearance for STX-1150 Phase 1 clinical trial (May 2026) | medcitynews.com · sec.gov |
| Partnership | Strategic collaborations with Sanofi (in vivo and ex vivo) and Eli Lilly (neurological/neuromuscular) | biospace.com · sec.gov |
| Production site | Uses third-party contract manufacturing organizations (CMOs) | sec.gov |
Independent sources: biospace.com · endpoints.news · medcitynews.com · scribetx.com · sec.gov · stockanalysis.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Genome editing | genome-engineering | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.